Loading...
GH Research PLC
GHRS•NASDAQ
Healthcare
Biotechnology
$14.50
$0.010(0.07%)
GH Research PLC (GHRS) Financial Performance & Income Statement Overview
Review GH Research PLC’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
0.00%
Net Income Growth
0.00%
Operating Cash Flow Growth
-26.84%
↓ 26.84%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-19.20%
↓ 19.20%
ROIC
-16.59%
↓ 16.59%
GH Research PLC (GHRS) Income Statement & Financial Overview
Review GH Research PLC's (GHRS) income statement with detailed quarterly and annual figures.
Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $80000.00 |
Cost of Revenue | $0.00 | $0.00 | $78000.00 | $80000.00 |
Gross Profit | $0.00 | $0.00 | -$78000.00 | $0.00 |
Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
R&D Expenses | $8.21M | $8.40M | $9.76M | $8.65M |
SG&A Expenses | $4.67M | $4.15M | $3.39M | $2.75M |
Operating Expenses | $12.94M | $12.62M | $13.22M | $11.40M |
Total Costs & Expenses | $12.94M | $12.62M | $13.22M | $11.48M |
Interest Income | $1.75M | $1.44M | $1.47M | $2.67M |
Interest Expense | $10000.00 | $181000.00 | $178000.00 | $179000.00 |
Depreciation & Amortization | $78000.00 | $79000.00 | $78000.00 | $80000.00 |
EBITDA | -$8.71M | -$12.02M | -$10.12M | -$7.41M |
EBITDA Ratio | $0.00 | $0.00 | $0.00 | -$142.47 |
Operating Income | -$12.94M | -$12.62M | -$13.22M | -$11.48M |
Operating Income Ratio | $0.00 | $0.00 | $0.00 | -$143.47 |
Other Income/Expenses (Net) | $4.14M | $507000.00 | $2.84M | $3.81M |
Income Before Tax | -$8.80M | -$12.11M | -$10.38M | -$7.67M |
Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | -$95.83 |
Income Tax Expense | $0.00 | $0.00 | $0.00 | -$1.00 |
Net Income | -$8.80M | -$12.11M | -$10.38M | -$7.67M |
Net Income Ratio | $0.00 | $0.00 | $0.00 | -$95.83 |
EPS | -$0.17 | -$0.23 | -$0.20 | -$0.15 |
Diluted EPS | -$0.17 | -$0.23 | -$0.20 | -$0.15 |
Weighted Avg Shares Outstanding | $52.03M | $52.03M | $52.03M | $52.03M |
Weighted Avg Shares Outstanding (Diluted) | $52.03M | $52.03M | $52.03M | $52.03M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan